Presentation is loading. Please wait.

Presentation is loading. Please wait.

Share your thoughts on this presentation with #IAS2019

Published bySugiarto Chandra Modified over 5 years ago

Similar presentations

Presentation on theme: "Share your thoughts on this presentation with #IAS2019"— Presentation transcript:

1

2 Share your thoughts on this presentation with #IAS2019
Evolution on HIV drug resistance surveillance in Brazil: a declining trend to celebrate Rosana Elisa Gonçalves Gonçalves Pinho, Nazle Mendonça Collaço Véras, Ana Roberta Pascom, José Boullosa, Fernanda Rick, Gerson Fernando Mendes Pereira Department of Diseases of Chronic Condition and Sexually Transmitted Infections, Secretariat for Health Surveillance, Ministry of Health of Brazil Share your thoughts on this presentation with #IAS2019

3 I have no conflicts of interest to disclosure.

4 Brazil’s Genotyping test offering
Pretreatment HIV genotyping test: pregnant woman, children, serodifferent couples, HIV/TB co-infected, seroconversion on PrEP and individuals initiating antiretroviral therapy with EFV. All individuals under ART experiencing virological failure Information System for Genotyping Network (Sisgeno)

5 52,658 PR-RT sequences from 44,806 individuals from 2008-2018
Methods/Results 52,658 PR-RT sequences from 44,806 individuals from 18+ ARV-experienced individuals Stanford HIVdb Program (High‐Level DRMs - Score = 60+) HIV subtype (Rega HIV Subtyping) Demographic and clinical characteristcs

6 HIV drug resistance amongst people taking ART decreased over the last decade

7 DR Mutations K103 – 27% (NNRTI) M184 – 27% (NRTI) M46 – 11% (PI)
I54 – 9% (PI) K65 – 8% (NRTI)

8 HIV resistance according to the number of drugs exposed before genotyping test

9 HIV resistance according to the number of drugs exposed before genotyping test

10 Distribution of HIV-1 Subtypes in Brazil
North Northeast Distribution of HIV-1 Subtypes in Brazil Center-West Southeast South

11 Resistance to ARV class according to the most frequent subtypes in Brazil

12

13 Conclusions Acquired HIV drug resistance decreased over the decade in Brazil. Continuous improvement of the monitoring of HIV drug resistance routine is particularly important to minimize the spread of resistance in country, specially related to new drugs, and thus to contribute to the control of the HIV epidemic.

14 Thank you!

Download ppt "Share your thoughts on this presentation with #IAS2019"

Similar presentations

Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.

Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.
World Health Organization Surveys of Transmitted and Acquired HIV Drug Resistance in Resource Limited Settings CROI 2011 S Bertagnolio*, K Kelley*, A Saadani.

World Health Organization Surveys of Transmitted and Acquired HIV Drug Resistance in Resource Limited Settings CROI 2011 S Bertagnolio*, K Kelley*, A Saadani.
Children and resistance to HIV: CHIPS data Dr Katherine Boyd on behalf of Collaborative HIV Paediatric Study (CHIPS) and the UK HIV Drug Resistance Database.

Children and resistance to HIV: CHIPS data Dr Katherine Boyd on behalf of Collaborative HIV Paediatric Study (CHIPS) and the UK HIV Drug Resistance Database.
Www.aids2014.org An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia 2005-2012.

An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia
Monitoring the emergence of resistance mutations in patients under salvage therapy with Raltegravir in Rio de Janeiro, Brazil: a six month follow-up Caroline.

Monitoring the emergence of resistance mutations in patients under salvage therapy with Raltegravir in Rio de Janeiro, Brazil: a six month follow-up Caroline.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A. www.bordernet.eu www.aidshilfe-potsdam.de.

BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Summary Slide Presentation Principles of HIV drug resistance for clinical management in South Africa Stott K, Michel J, de Oliveira T. Principles of HIV.

Summary Slide Presentation Principles of HIV drug resistance for clinical management in South Africa Stott K, Michel J, de Oliveira T. Principles of HIV.
1 Rationale and Uses For a Public HIV Drug Resistance Database Bob Shafer, MD Professor of Medicine and by Courtesy Pathology (Infectious Diseases)

1 Rationale and Uses For a Public HIV Drug Resistance Database Bob Shafer, MD Professor of Medicine and by Courtesy Pathology (Infectious Diseases)
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.

Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.
HIV Drug Resistance in Well-Resourced Settings Vincent Marconi, MD.

HIV Drug Resistance in Well-Resourced Settings Vincent Marconi, MD.
Phylogenetic Insight into HIV Transmission Networks in a Southeastern US Cohort Ann Dennis 1, Stéphane Hué 2, Christopher Hurt 1, Sonia Napravnik 1, Deenan.

Phylogenetic Insight into HIV Transmission Networks in a Southeastern US Cohort Ann Dennis 1, Stéphane Hué 2, Christopher Hurt 1, Sonia Napravnik 1, Deenan.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable 23-24 June 2008.

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
HIV Drug Resistance Control: the Latin American experience Giovanni Ravasi Pan-American Health Organization, Brazil International AIDS.

HIV Drug Resistance Control: the Latin American experience Giovanni Ravasi Pan-American Health Organization, Brazil International AIDS.
Global HIV Resistance: The Implications of Transmission

Global HIV Resistance: The Implications of Transmission
Application in professional activity of theoretical knowledge and practical skills acquired during residency program Dr. Ion Bîrcă National Center of Public.

Application in professional activity of theoretical knowledge and practical skills acquired during residency program Dr. Ion Bîrcă National Center of Public.
Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.

Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.
HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Linking HIV-1 and Antiretroviral Drug Resistance Surveillances: Low Prevalence of HIV-1 Drug Resistance in Peru Lama JR 1, Suarez L 2, Laguna A 3, Acuña.

Linking HIV-1 and Antiretroviral Drug Resistance Surveillances: Low Prevalence of HIV-1 Drug Resistance in Peru Lama JR 1, Suarez L 2, Laguna A 3, Acuña.

Similar presentations

Ads by Google